Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 4228 in Advanced Prostate Cancer
NCT06395753Phase 2Completed
- Sponsor
- Debiopharm
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of Debio 4228 in prostate cancer (PCa) (3 cohorts), sponsored by Debiopharm. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-time Curve Over 12 weeks and 2 more. Started May 2024; status: completed.
02
Drugs
Debio 4228
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06395753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06395753.